Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Peripheral T-cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Tipifarnib

Bridget Martell, MD

Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will be administered orally until disease progression.

This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with relapsed or refractory PTCL. The first 18 subjects may be of the following PTCL sub-types: PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK-positive and negative anaplastic large cell lymphoma (ALCL), hepatosplenic T-cell lymphoma, enteropathy-associate T-cell lymphoma (EATL), extranodal natural killer (NK) T-cell lymphoma, nasal type and subcutaneous panniculitis-like T-cell lymphoma. The AITL expansion cohort (N=32) will enroll only subjects with AITL. An additional cohort of patients (N=12) expressing the wild type CXCL12 3' UTR will be enrolled in order to explore the benefits of tipifarnib treatment observed in patients having an absence of this gene variation or single nucleotide variation (SNV).

Tumor response assessments will be conducted according to Lugano Classification and/or mSWAT criteria.

Tumor assessments will be performed approximately every 8 weeks (cycles 2-6) and at least once approximately every 12 weeks thereafter (Cycles 9, 12, 15, etc.), and will continue until disease progression. Subjects experiencing a complete response may be considered for bone marrow transplantation. Upon disease progression, all subjects will be followed for survival and the use of subsequent therapy. All subjects will be followed for safety during treatment and up to approximately 30 days after treatment discontinuation or until before the initiation of another anti-cancer therapy. Additional follow up may be implemented until the subject recovers from any emergent treatment related toxicity or the adverse event is considered irreversible by the investigator.

Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.

An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Response assessments according to Lugano Classification and/or mSWAT

To determine the antitumor activity in terms of PFS in subjects with relapsed/refractory PTCL

To determine the antitumor activity in terms of DOR in subjects with relapsed/refractory PTCL

To evaluate the safety and tolerability of tipifarnib in subjects with relapsed/refractory PTCL

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.	NCT02464228	Relapsed or Ref...	Tipifarnib	18 Years -	Kura Oncology, Inc.
Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.	NCT02464228	Relapsed or Ref...	Tipifarnib	18 Years -	Kura Oncology, Inc.

Spots Global Cancer Trial Database for wild type cxcl12 3' utr